1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > Global Injectable Drug Delivery Partnering 2010-2015

Global Injectable Drug Delivery Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

Provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

Injectable Drug Delivery Partnering 2010-2015 report provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.
Trends in injectable drug delivery partnering deals
Top injectable drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

Injectable Drug Delivery Partnering 2010-2015 provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter injectable drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual injectable drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of injectable drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in injectable drug delivery dealmaking since 2010

Chapter 3 is the most popular chapter that includes details of average headline, upfront, milestone and royalty terms.

Chapter 4 provides a review of the leading injectable drug delivery deals since 2010. Deals are listed by headline value, most active of all biopharma companies and signed by big pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive directory of injectable drug delivery partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in injectable drug delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about injectable drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.

Report scope

Injectable Drug Delivery Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to injectable drug delivery trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in injectable drug delivery dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 150 injectable drug delivery actual deal records
The leading injectable deals by value since 2010

In Injectable Drug Delivery Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Therapy type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Injectable Drug Delivery Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of injectable drug delivery deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 150 actual deal records entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Injectable Drug Delivery Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in injectable drug delivery dealmaking

2.1. Introduction
2.2. Injectable drug delivery partnering over the years
2.3. Big pharma injectable drug delivery dealmaking activity
2.4. Injectable drug delivery partnering by industry type
2.5. Injectable drug delivery partnering by deal type
2.6. Injectable drug delivery partnering by disease type

Chapter 3 -Average financial deal terms for injectable drug delivery partnering

3.1 Injectable drug delivery deals by headline values
3.2 Injectable drug delivery upfront payments
3.3 Injectable drug delivery milestone payments
3.4 Injectable drug delivery royalty rates

Chapter 4 - Leading injectable drug delivery deals

4.1. Introduction
4.2. Most active in injectable drug delivery partnering
4.3. Top injectable drug delivery deals by value

Chapter 5 - Injectable drug delivery partnering dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By stage of development
5.5. By industry sector
5.6. By therapy area
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products

Table of figures

Figure 1: Injectable drug delivery partnering since 2010
Figure 2: Big pharma - top 50 - Injectable drug delivery deals 2010 to 2015
Figure 3: Big pharma injectable drug delivery deal frequency - 2010 to 2015
Figure 4: Injectable drug delivery partnering by industry sector since 2010
Figure 5: Injectable drug delivery partnering by deal type since 2010
Figure 6: Injectable drug delivery partnering by disease type since 2010
Figure 7: Injectable drug delivery deals with a headline value
Figure 8: Injectable drug delivery deals with an upfront value
Figure 9: Injectable drug delivery deals with a milestone value
Figure 10: Injectable drug delivery deals with a royalty rate value
Figure 11: Active injectable drug delivery dealmaking activity- 2010 to 2015
Figure 12: Top injectable drug delivery deals by value since 2010

For the full list of companies mentioned in this report, please contact enquiry@currentpartnering.com

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The North American drug delivery technologies market is projected to reach USD 758.7 billion by 2021 from USD 520.0 billion in 2016, at a CAGR of 6.5% during the forecast period. Major factors contributing ...

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The syringes market is expected to reach USD 15.99 billion by 2021, at a CAGR of 8.7% from 2016 to 2021. The syringes market is primarily driven by the high prevalence of chronic diseases across the globe. ...

Injectable Drug Delivery Market Analysis, By Device Type, By Formulation, By Therapeutic Use, By End-user Application, By Region And Segment Forecasts From 2013 to 2024

Injectable Drug Delivery Market Analysis, By Device Type, By Formulation, By Therapeutic Use, By End-user Application, By Region And Segment Forecasts From 2013 to 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The global injectable drug delivery market is expected to reach USD 931.1 billion by 2024, according to a new report by Grand View Research, Inc. The increase in number of chronic diseases like diabetes ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.